| Identification | Back Directory | [Name]
LOBEGLITAZONE | [CAS]
607723-33-1 | [Synonyms]
LOBEGLITAZONE
2,4-Thiazolidinedione, 5-[[4-[2-[[6-(4-methoxyphenoxy)-4-pyrimidinyl]methylamino]ethoxy]phenyl]methyl]-
5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
(5R)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione | [Molecular Formula]
C24H24N4O5S | [MOL File]
607723-33-1.mol | [Molecular Weight]
480.54 |
| Chemical Properties | Back Directory | [Melting point ]
165-167 °C | [Boiling point ]
711.0±60.0 °C(Predicted) | [density ]
1.336±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
6.35±0.50(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Lobeglitazone is used in anti-diabetes mellitus pharmacological management. | [Definition]
ChEBI: Lobeglitazone is an aromatic ether. | [in vivo]
Lobeglitazone (1-10 mg/kg, po for 8 weeks) exhibits anti-atherosclerotic property in ApoE?/? mouse models[4].
| Animal Model: | ApoE?/? mouse aortic atherosclerosis models[4] | | Dosage: | 1-10 mg/kg | | Administration: | po for 8 weeks | | Result: | Reduced aortic arch plaques. |
| [IC 50]
PPARγ: 137.4 nM (EC50); PPARα: 546.3 nM (EC50) |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|